改良Glasgow预后评分对非小细胞肺癌胸腔镜肺叶切除术后的预后价值

目的探讨术前改良Glasgow预后评分(m GPS)对非小细胞肺癌(NSCLC)患者胸腔镜肺叶切除术术后的预后价值。方法纳入确诊为NSCLC并进行胸腔镜肺叶切除的患者共139例。m GPS评分的数值根据C反应蛋白和白蛋白水平分为0、1、2三组,分析m GPS评分以及其他临床指标与术后生存时间的关系。结果139例NSCLC患者中,23例(16.5%)的m GPS=1,35例(25.2%)的m GPS=2,高龄、晚期、未接受放化疗与预后相关,m GPS=2是预后差的独立因素。结论术前高m GPS评分是影响非小细胞肺癌胸腔镜肺切除术预后的独立危险因素,m GPS评分高提示预后不良。在进行非小细胞肺癌治疗相关选择时,必须考虑患者的全身性炎症反应。

Prognostic Efficacy of Modified Glasgow Prognostic Score (mGPS) in Non-small-cell Lung Cancer (NSCLC) after Thoracoscopic Obectomy

Objective To evaluate the prognostic efficacy of modified Glasgow prognostic score(m GPS)in non-small-cell lung cancer(NSCLC)after thoracoscopic obectomy.Methods A total of 139 NSCLC patients after thoracoscopic obectomy were enrolled in this study.The m GPS was determined by levels of serum albumin and C reactive protein and was divided into 0,1 and 2 groups.The relationship of m GPS or other clinical parameters with survival time was evaluated.Results Among all patients,m GPS in 23(16.5%)patients equaled to 1 and 35(25.2%)eaqualed to 2.Old age,late stage and non-radiochemotherapy were associated with cancer prognosis and m GPS=2 was an independent indicators for poor prognosis.Conclusion High m GPS before surgery is an independent risk factor for the prognosis of NSCLC patients after thoracoscopic obectomy and high m GPS indicated a poor prognosis.The status of systematic inflammation response should be noticed when selecting the treating methods of NSCLC.